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Aim: The aim of this study was to investigate whether a disease registry could serve 
as a suitable alternative to clinical studies to investigate safety of orphan drugs in 
children.
Methods: We used individual patient data from previously untreated patients (PUPs) 
with severe haemophilia A from the factor VIII (rAHF-PFM)-clinical study and the 
PedNet registry. The primary outcome was the patient characteristics at entry and 
the difference in inhibitor development between the clinical study and the registry-
based study at 50 exposure days.
Results: Clinical study patients more often had a positive family history of inhibitors 
(31% vs 10%) and a high-risk F8 genotype (82% vs 63%). In the clinical study 41/55 
(75%) and in the registry-based study 162/168 (96%) patients reached 50 exposure 
days. Inhibitors developed in 16 of the 41 patients in the clinical study (39%) vs 44 of 
the 162 patients in the registry-based study (27%); seven patients (7%) vs 28 patients 
(17%) had high-titre inhibitors. The risk of developing an inhibitor during the first 50 
exposure days was similar (HR 1.04; 95% CI 0.56-1.94), when adjusted for family his-
tory of inhibitors, F8 gene mutation and intensive treatment at first exposure.
Conclusion: In the registry-based study, patient numbers and completeness of 
follow-up were higher. The risk of developing an inhibitor to a single product was 
comparable. Although the sample size of this study was too small to conclude on dif-
ferences in high- or low-titre inhibitors, this suggests that a registry could serve as 
a more suitable source for evaluation of high-titre inhibitors in the setting of factor 
VIII deficiency.
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1  | INTRODUC TION
In the field of orphan diseases, clinical trials are inherently small 
and relatively often use non-randomized study designs.1,2 Disease 
registries may be a reasonable alternative for small, single-arm 
clinical studies to evaluate safety and efficacy of a drug. A great 
benefit of registries is that they include ‘real-life’ patients, and are 
suited for monitoring safety and beneficial effects over a longer 
period.3 Within the regulatory field, the Patient Registry Initiative 
of the European Medicine Agency is exploring the use of patient 
registries. This initiative supports a systematic approach for a bet-
ter use of registry data for the benefit-risk evaluation of medicines, 
mostly post-marketing.4,5 To retrieve high-quality registry data, 
key aspects are a comprehensive enrolment of patients, avoidance 
of selection bias, collection of essential core data and complete-
ness of data.5
Haemophilia A is a rare disease, with a prevalence of 1:5000 
new-born males, for which single-arm clinical studies have sup-
ported market approval of (recombinant) clotting factors that re-
place the deficient factor VIII.6 In various registries, patients with 
haemophilia are closely monitored for the occurrence of antibod-
ies against administered clotting factor, so-called ‘inhibitors’. 
The occurrence of inhibitor development in previously untreated 
patients (PUPs) has been reported to be as high as 25%-35%.7,8 
There is an ongoing debate as to whether plasma products might 
be associated with a lower risk of inhibitor development in com-
parison with recombinant products.7,9,10 Different inhibitor in-
cidences between individual recombinant products have also 
been published.7-9,11 Major limitations to the interpretation of 
results from previous clinical studies were due to differences in 
study design, patient selection and a short follow-up.12 Recently, 
data from historic clinical studies were investigated. These data 
proved unsuitable for comparing immunogenicity between prod-
ucts, due to differences in study design, diversity in enrolled 
patient populations and small numbers of included patients.13 
Lately, a number of new factor VIII products have been licensed, 
and many new products are being developed.14 To investigate 
the occurrence of inhibitor development for these products, it 
might be difficult to recruit sufficient PUPs in clinical studies 
in an appropriate time frame. This knowledge has recently led 
to a change in the guideline for the investigation of factor VIII 
products. To retrieve long-term safety data in PUPs, core data 
elements should be collected in patient registries rather than in 
small clinical trials.6
To investigate whether a registry-based study could serve 
as a reasonable alternative for a single-arm clinical study, we 
evaluated inhibitor development in PUPs with severe haemo-
philia A using the same recombinant FVIII product in a clinical 
study and a registry-based study. We selected the factor VIII 
(rAHF-PFM)-clinical study, because the study was performed 




In previously untreated patients (PUPs) with severe haemophilia A 
using factor VIII (rAHF-PFM), we compared the development of anti-
factor VIII antibodies (inhibitors), using individual patient data from 
the factor VIII (rAHF-PFM) PUP-clinical study and the PedNet regis-
try. We checked all core data elements required in the guideline for 
regulatory PUP studies, and compared core data elements relevant 
for patient characteristics and inhibitor formation in the two study 
populations.
2.2 | Data sources
2.2.1 | The clinical study: factor VIII (rAHF-PFM) 
PUP-clinical study
The factor VIII (rAHF-PFM) clinical study was a prospective clini-
cal study including 55 patients treated with human recombinant 
FVIII octocog alfa from 24 haemophilia centres (www.clini caltr ials.
gov trial no: NCT00157157).15 The participants in this clinical study 
received a specific intervention (human recombinant FVIII octocog 
alfa) according to the protocol created by Takeda. The first patient 
entered the study on 1 April 2004, and the last patient exited on 11 
September 2009. Takeda provided the individual patient data of this 
clinical study to us after they had been fully anonymized.
In line with the definition used in the PedNet study, patients that 
received 1-4 infusions of rAHF-PFM before entering the study were 
defined as previously untreated patients (PUPs).
2.2.2 | The registry-based study: PedNet 
Haemophilia Registry
As of January 2018, the PedNet Haemophilia Registry had included 
1035 patients with severe haemophilia A (factor VIII activity at base-
line percentage ≤1%) from 31 haemophilia centres (www.pednet.
eu, www.clini caltr ials.gov trial no: NCT02979119).16,17 To provide a 
contemporaneous comparison to the clinical study, we selected all 
PUPs treated with human recombinant FVIII octocog alfa who were 
born between 2000 and 2009. Participants included in the registry 
received the intervention (human recombinant FVIII octocog alfa) as 
part of their routine medical care according to the protocol created 
by PedNet. For this analysis, we used the follow-up data available 
in January 2018. Sixty-one PedNet patients were selected from six 
centres that also participated in the clinical study. Due to privacy 
regulations, we obviously did not have access to, for example initials 
or date of birth to verify whether a patient was included both in the 
clinical study and in the registry. We matched patients on the fac-
tors F8 genotype mutation (yes/no), family history of inhibitors (yes/
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no) and treatment intensity (yes/no). In total, 70 (2 × 35) matched 
patients matched on these three factors. Importantly, 35 matched 
patients from the PedNet registry were from centres that did not 
participate in the clinical study. Thus, this excludes the possibility 
of an overlap of patients from the clinical study and the PedNet 
registry.
2.3 | Data
We extracted core data elements of the PUP populations from the 
clinical study and the registry as listed in the guideline.6 For this 
study we selected the key patient characteristics of age, gender, 
type of haemophilia, severity of haemophilia (<1% factor VIII activ-
ity), family history of haemophilia (yes/no), family history of inhibitor 
development (yes/no), product, F8 gene mutation (high risk/low risk) 
and intensity of treatment at first exposure (yes/no). A high-risk F8 
gene mutation was defined as genotypes with large deletions, non-
sense mutations and intron inversions. A low-risk F8 gene mutation 
was defined as genotypes with small deletions and insertions, mis-
sense mutations, and splice-site mutations.15,17 Intense treatment at 
first exposure was defined as an episode of treatment with factor 
VIII for a bleed or surgery on at least five consecutive days.
In addition, we collected the duration of treatment (number of 
exposure days and calendar days) and the number of patients fol-
lowed until exposure days 20 and 50.
2.4 | Outcome parameter
The primary outcome was the percentage of patients developing 
clinically relevant inhibitors to factor VIII (rAHF-PFM) up to 20 and 
up to 50 exposure days. A clinically relevant inhibitor is defined as at 
least two independent positive inhibitor tests with decreased in vivo 
recovery of factor VIII levels. For the registry laboratory, results are 
used from the individual laboratories (according to the used inhibitor 
assay and their cut-off level)17 and from a central laboratory for the 
clinical study.15 High-titre inhibitor was defined as a peak inhibitor 
titre of at least 5 Bethesda units per millilitre. Testing was performed 
at least every five exposure days during the first 20 exposure days 
and thereafter at least every 3 months until 50 exposure days were 
reached.
The secondary outcome was time to (high/low) inhibitor devel-
opment defined as the number of exposure days prior to the first 
positive inhibitor test. An exposure day was defined as a day with 
one or more infusions of factor VIII.
2.5 | Analyses
We used descriptive statistics and chi-square tests to compare the 
patient characteristics of the PUP populations in the clinical study 
and the registry-based study. Using logistic regression, we compared 
the percentage of patients developing an inhibitor up to 20 and 50 
exposure days (ED20 and ED50) unadjusted and adjusted for poten-
tial confounders. In this study, we adjusted for family history of in-
hibitor development (yes/no), F8 gene mutation (high risk/low risk) 
and intensive treatment at first exposure (yes/no). We performed 
complete case analysis.
The time to inhibitor development was visualized with a Kaplan-
Meier plot, censored at 50 exposure days. Cox regression was used 
to calculate crude and adjusted hazard ratios for inhibitor develop-
ment, using the same potential confounders as in the logistic re-
gression analysis. To make the groups comparable for the exposure, 
subjects were censored at 50 exposure days and subjects, who did 




In the clinical study 55 PUPs and in the registry-based study 168 
PUPs with severe haemophilia A were included. Core data elements 
were available in line with the EMA guideline.6 The most important 
patient characteristics that must be documented were included in 
the clinical study and the registry-based study and are shown in 
Table 1. All patients were male and used the same recombinant fac-
tor VIII product rAHF-PFM during all exposure days. In the clinical 
study, 17/55 (31%) patients had a positive family history of inhibi-
tors vs 16/168 (10%) in the registry. The number of patients with 
a high-risk F8 gene mutation in the clinical study was 45/55 (82%) 
vs 105/168 (63%) in the registry-based study. In the clinical study 
8/55 (15%) and in the registry-based study 29/168 (17%) patients 
received intensive treatment at first exposure.
3.2 | Treatment period
In the clinical study 48 (87%) and in the registry-based study 164 
(98%) patients received 20 exposure days, or developed an inhibitor 
within that period. Forty-one (75%) patients in the clinical study and 
162 (96%) in the registry-based study reached 50 exposure days or 
developed an inhibitor (Figure 1 and Table 2).
3.3 | Inhibitor development
In the clinical study 11 out of 48 patients (23%) and in the registry-
based study 37 out of 164 patients (23%) developed inhibitory anti-
bodies within 20 exposure days (OR 1.02 [95% CI 0.47-2.20]). When 
adjusted for family history of inhibitors, F8 genotype and treatment 
intensity the odds ratio was 0.56 (95% CI 0.22-1.43).
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In total, 60 patients developed inhibitory antibodies within the 
first 50 exposure days: in the clinical study 16 out of 41 (39%) and 
in the registry 44 out of 162 (27%). The odds ratio was 1.72 (95% CI 
0.84-3.51). When adjusted for family history of inhibitors, F8 geno-
type and treatment intensity, the odds ratio was 1.22 (95% CI 0.54-
2.75). In the clinical study, 7/41 (17%) patients developed a high-titre 
of antibodies while in the registry-based study, this occurred in 28 
of 162 patients (17%). Patients developed inhibitor antibodies after 
a median of 15 exposure days in the clinical study (Q1-Q3 10-22 
EDs) and in the registry-based study after 14 exposure days (Q1-
Q3 10-17 EDs; Table 2). The time between first exposure day and 
inhibitor development was 5.5 months in the clinical study (Q1-Q3 
3.5-10.3), and in the registry-based study, it was 3.1 months (Q1-Q3 
1.4-7.9).
The Kaplan-Meier graph shows the number of exposure days 
to inhibitor development (Figure 1). We did not observe any differ-
ences in inhibitor incidences of patients during the first 20 exposure 
days. However, after 20 exposure days, the risk to develop an inhib-
itor was higher for patients in the clinical study.
When using Cox regression analysis, the hazard ratio for inhibitor 
development was 1.52 (95% CI 0.86-2.69) for patients in the clinical 
study compared to those in the registry-based study. After adjusting 
for family history of inhibitors, treatment intensity and F8 genotype, 
the hazard ratio was 1.04 (95% CI 0.56-1.94).
4  | DISCUSSION
At study entry, patient characteristics were different between the 
clinical study and the registry-based study. In the clinical study, 
the prevalence of family history of inhibitors was higher and more 
patients had a high-risk gene mutation. In the clinical study, only 
75% of the 55 patients reached 50 exposure days. The follow-up 
in the registry-based study was more complete with 96% of all 168 
patients reaching 50 exposure days. In the clinical study, more pa-
tients developed an inhibitor; however, the percentage of patients 
that developed a high-titre inhibitor was comparable. The risk of de-
veloping an inhibitor during the first 50 exposure days was similar 
Characteristic
Factor VIII (rAHF-PFM) PUP-
clinical study (N = 55)
PedNet registry-based 
study (N = 168)
Previous untreated patienta  
(PUP)
55 (100%) 168 (100%)
Factor VIII activity at baseline
<1% 53 (96%) 168 (100%)
>1 and <2% 1 (2%) 0
>2% 1 (2%) 0
Age at first exposure (mo, 
median, IQR)
9.0 (3.0-11.0)b  9.9 (5.3-13.6)
Family history of haemophilia
Yes NA 88 (52%)
No NA 79 (47%)
Unknown 55 (100%) 1 (1%)
Family history of inhibitors
Yes 17 (31%) 16 (10%)
No 35 (64%) 140 (83%)
Unknown 3 (5%) 12 (7%)
F8 genotype
High-risk 45 (82%) 105 (63%)
Low-risk 10 (18%) 56 (33%)
Unknown 0 7 (4%)
Intensive treatment on first exposure days for >5 d
Yes 8 (15%) 29 (17%)
No 47 (85%) 139 (83%)
Note: Patient characteristics for patients from the clinical study and the registry-based study, using 
the same rFVIII product.
aIn the factor VIII (rAHF-PFM) PUP-clinical study, MTPs were defined as patients using the same 
recombinant FVIII product before the start of the clinical study; in this study, we defined MTPs as 
patients that received any exposure of another product before entering the study for rAHF-PFM. 
bAge is defined in months at time of baseline (clinical study). 
TA B L E  1   Patient characteristics
     |  5JONKER Et al.
(HR 1.04; 95% CI 0.56-1.94), when adjusted for the main potential 
confounders.
This is, as far as we know, the first direct comparison of inhibitor 
development in PUPs, either participating in a clinical study or followed 
in a registry. Patients in both data sets were treated during the same 
time period, between 2000 and 2009, and used the same recombinant 
factor VIII product. Both in the clinical study and in the PedNet regis-
try, the core data elements collected were in line with the guideline.6 
Patients in the registry-based study were followed until January 2018, 
which led to a higher number of patients reaching 50 exposure days 
(96%), while this was only 75% for the clinical study. In a systematic 
review evaluating the incidence of inhibitor development in 24 pub-
lished clinical studies in PUPs, only in 10 studies was the duration of 
the treatment longer than 50 exposure days.18 In registries, the fol-
low-up of patients is mostly longer, with >90% of the patients followed 
for more than 50 exposure days.8,11 In the PedNet registry, patients 
were followed for up to 1000 exposure days. Recently published data 
showed that 79% of all inhibitors developed within 20 exposure days 
and 18% between 20 and 50 exposure days.16
In the light of the discussion for the difference in risk rate for 
plasma and recombinant products, it is interesting that the inhibitor 
incidence found in both our data sets with a single recombinant FVIII 
product was similar to that reported for the plasma products in the 
SIPPET study.10 It should be acknowledged though that small num-
bers and selection of patients are important factors that may have 
influenced the results reported here. Summary statistics of clinical 
studies have been published via meta-analyses and systemic re-
views, comparing inhibitor rates.12 The contribution of this paper is 
that we provide a direct comparison of individual data of a published 
clinical study and compare that to a study embedded in a disease 
registry. The completeness of the data illustrates that in the field 
of haemophilia, a well-defined prospective registry could serve as 
a good data source to study long-term (safety) data of, for example 
factor VIII products.
F I G U R E  1   Kaplan-Meier curve for 
inhibitor development. Kaplan-Meier 
curves for inhibitor development in 
PUPs from a clinical study (broken line) 
and from a registry-based study (solid 
line). The table below indicates patients 
numbers with inhibitor development and 
the patient numbers on treatment at the 
corresponding exposure days. Patients 
not followed up to 50 exposure days are 
right censored.
Patients with inhibitor 
development 0 10 20 30 40 50
Clinical study 0 3 11 14 16 16
Registry-based study 0 9 37 42 44 44
Patients at risk 0 10 20 30 40 50
Clinical study 55 47 37 31 26 25
Registry-based study 168 157 127 120 118 118
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An issue of clinical studies is the difficulty of recruiting PUPs 
with severe haemophilia A. In full cohorts such as FranceCoag 
Network, UKHCDO National Haemophilia Database and PedNet, 
more than 50% of the patients were diagnosed with a negative 
family history.7,8,11 These patients are diagnosed after the onset 
of bleeding and therefore excluded from clinical studies. In un-
selected cohorts, only 10% of the patients had a positive fam-
ily history of inhibitors19,20 and about 60% of the patients had a 
high-risk F8 genotype.21 In the clinical study, more patients had a 
positive family history of inhibitors and a high-risk F8 genotype; 
this might have increased the a priori risk of inhibitor development 
and reduces extrapolation to the general population.22 The patient 
characteristics within the registry-based study seem to be more 
representative of ‘real-life’ patients from the described full cohorts 
above.
A limitation of this paper is that we compared data from only one 
clinical study and one registry-based study. We selected this clinical 
study because the number of patients included in that study was 
larger than other PUP studies and factor VIII (rAHF-PFM) is widely 
used daily clinical practice and in patients included in PedNet. Further 
comparisons between different concentrates and different study and 
registry populations may strengthen our conclusions. Obviously, is-
sues on study design, such as, duration of follow-up and inter-labora-
tory variations, may affect observed inhibitor formation. We, however, 
strongly believe that high-titre inhibitors will usually be diagnosed 
accurately and that registries could substitute for clinical trials in the 
case of high-titre inhibitors. Despite the sample size of this study was 
too small to conclude on this, therefore using similar data standards, 
adhering to those standards and publishing these standards will make 
data more readily exchangeable between registry (and clinical) stud-
ies. In line with McGettigan et al, we think that the value of registries 
can be increased by clearly described operational proposals on patient 
registry data, quality assurance processes, governance and stake-
holder communication.5 This study thus illustrates that in the clinical 
study and the registry-based study, the same patient characteristics 
and outcome parameters were collected, in line with the guideline.6
With all the new products that will be marketed, it is crucial that 
centres collect data on all PUPs with severe haemophilia and share 
their results.23 Products can only be compared independently if data 
collection methodology is similar and includes all potential confound-
ing factors.23 The most important limitation of observational drug 
studies is that different products are given to patients with different a 
priori inhibitor risk.24 Rather than performing single-arm PUP studies 
for separate products, a controlled study (thus comparing two prod-
ucts and adjusting for confounders) within a registry would, in our 
view, be feasible and may be more efficient.25 We believe that fur-
ther optimization may be achieved by performing randomized studies 
within registries.25
Outcome
Factor VIII (rAHF-PFM) PUP-
clinical study (N = 55)
PedNet registry-based 
study (N = 168)
Number of patients (number, %)
At ED20a  48 (87%) 164 (98%)
At ED50 41 (75%) 162 (96%)
Number of ED at inhibitor development (median, Q1-Q3)
All 15 (10-22) 14 (10-17)
High-titre 13 (8-16) 14 (10-17)
Number of patients with inhibitor development (number, %)b 
At ED20 11 (23%) 37 (23%)
At ED50 16 (39%) 44 (27%)
Number of patients with inhibitor developmentc  (number, %)
Low-titre 9 (22%) 16 (10%)
High-titre 7 (17%) 28 (17%)
Time between first exposure 
day and inhibitor development 
(mo, median, Q1-Q3)
5.5 (3.5-10.3) 3.1 (1.4-7.9)
Note: aExposure Day (ED) is defined as a calendar day during which one or more infusions were 
given; for the clinical study, exposure prior to the start of clinical study was factored into the 
calculation of the exposure days. 
bThe percentage of inhibitor development up to ED20 or ED50. The percentage is the number of 
patients with an inhibitor divided by the number of patients that reached ED20 or ED50. 
c Inhibitor development up to ED50: All inhibitor: defined as the occurrence of at least two positive 
inhibitor titres combined with a decreased factor VIII recovery; High-titre inhibitor: defined as 
a peak inhibitor titre of at least 5 Bethesda units per millilitre. The percentage is the number of 
patients with an inhibitor divided by the number of patients that reached ED50.  
TA B L E  2   Duration of treatment and 
inhibitor development in the Factor VIII 
(rAHF-PFM) PUP-clinical and the PedNet 
registry-based study
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5  | CONCLUSION
Our paper provides an example showing that patient characteris-
tics were slightly different between a clinical study and a registry-
based study. In the clinical study, a higher percentage of patients 
developed an inhibitor. The number of withdrawals was higher in 
the clinical study; the completeness of the follow-up was better 
in the registry. This study indicates that registries like PedNet 
are potentially useful in assessing the inhibitor developments in 
treatments for haemophilia and may serve as an alternative to un-
controlled clinical studies for evaluation of high-titre inhibitors. 
Although the sample size of this study was too small to conclude 
on differences in high- or low-titre inhibitors, this paper contrib-
utes to the discussion for the use of registry-based studies to as-
sess long-term safety data.
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